RxDoctor Payments Data

Robert Gutman, MD

Urogynecology and Reconstructive Pelvic Surgery · Baltimore, MDNPI 1043268501

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $19,646 of the $28,406 with a category attached, or 69.2%. Boston Scientific accounts for 65.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $9,557 and has fallen 92.6% since, to $704 in 2025.

$28,406in general payments, 2019–2025

Across 132 payments — averaging $215.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$19K
  • Coloplast$8K
  • Axonics, Inc.$1K
  • Sumitomo Pharma America, Inc.$222
  • AbbVie$221
  • Caldera Medical, Inc$134
  • plus $336 from 10 others
$58,918in research payments, 2019–2025

Across 10 payments — averaging $5891.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$59K

What the payments were for

  • Consulting fees$19,64669%
  • Travel & lodging$3,04711%
  • Food & beverage$5,50719%
  • Education$1511%
  • Gifts$360%
  • Entertainment$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$215,982
Medicare patients
453
Services billed
1,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron124$125,693
MyrbetriqMirabegron98$98,651
Trospium Chloride ErTrospium Chloride84$20,346
Estradiol149$10,686
Trospium Chloride50$3,813
Solifenacin Succinate75$3,596
Clobetasol Propionate19$930
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim26$379
Cephalexin30$350
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$276
Oxybutynin Chloride ErOxybutynin Chloride12$272
Oxycodone Hcl27$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$222$125,693124 claims
Astellas Pharma US IncMyrbetriq$17$98,65198 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Marylandon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →